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Background: Although hemodialysis (HD) is a suggested risk factor for stent thrombosis, its contribution
to local vessel healing after drug-eluting stent (DES) implantation is unclear.
Methods: A total of 121 patients (152 lesions treated with DES) who underwent 8-month follow-up
coronary angiography with optical coherence tomography (OCT) were enrolled, and the ﬁndings were
compared between patients with andwithout HD. Tomatch baseline differences, mid-termOCT ﬁndings
of 42 propensity score-matched lesions (21 non-HD vs. 21 HD) were compared. Effects of HD on the
efﬁcacy of antiplatelet therapy were also evaluated by VerifyNow assay (Accumetrics, San Diego, CA,
USA).
Results: Patients with HD had a signiﬁcantly higher rate of thrombus formation than those with-
out (64% vs. 33%, p=0.007), although the baseline parameters and lesion characteristics differed
between the groups. Multivariate logistic regression analysis revealed that HD was associated with
an increased risk of thrombus formation (odds ratio 5.991, 95% conﬁdence interval: 1.972–18.199,
p=0.002). Even after propensity-matching for patient background and balancing of angiographic and
OCT variables, the risk of thrombus formation remained signiﬁcantly higher in HD patients. The P2Y12-
reaction unit was signiﬁcantly increased after HD (Pre HD: 211±75 vs. Post HD: 262±59, p=0.01),
but patients without HD showed no increase during the same elapsed time (221±88 vs. 212±96,
p=0.19).
Conclusions:HD is a potential risk factor for subclinical thrombus attachment after DES therapy. Systemic
problems, such as residual platelet reactivity, associated with HD as well as local vessel features in HD
patients might contribute to the increased incidence of thrombus attachment and subsequent onset of
thrombotic event after DES implantation.
© 2ntroduction
Although implantation of drug-eluting stents (DES) signif-
cantly reduces restenosis compared with bare-metal stents
n a wide range of patient populations [1], hemodialysis (HD)
ontinues to be associated with an increased risk of restenosis
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and an unfavorable clinical outcome after DES deployment [2–5].
Because the detailed vessel response after DES implantation in
patients undergoing HD therapy has not been fully elucidated, the
mechanisms of such interactions remain unclear. In the present
study, we assessed the relationship between HD and local vessel
conditions before and after DES deployment using a large-scale
single center optical coherence tomography (OCT) database
pooled in the Kobe University OCT Registry. Also, to assess the
possible impact of HD treatment on the efﬁcacy of antiplatelet
therapy, responsiveness to antiplatelet therapy was also evaluated
using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA,
USA).
llege of Cardiology.
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Genomic DNA was extracted from whole blood using the com-
mercially available QIAampTM DNA Blood Mini kit (QIAGEN N.V.,
Venlo, The Netherlands) according to the manufacturer’s instruc-
tions. CYP2C19*2 (681G>A) or *3 (636G>A) polymorphisms were6 A. Konishi et al. / Journal
aterials and methods
tudy population and methods
BetweenApril 2006andApril 2010, a total of516patientsunder-
ent elective percutaneous coronary intervention (PCI) with DES
Cypher, Cordis Corp., Miami Lakes, FL, USA; TAXUS®, Boston Sci-
ntiﬁc, Natick, MA, USA; and XIENCE VTM, Abbott Vascular, Inc.,
anta Clara, CA, USA) for de novo native coronary lesions (822
ES). Of those, 342 patients underwent prospectively scheduled
ollow-up angiography as a routine angiographic follow-up widely
erformed in Japan. To ensure patient safety during OCT, patients
ith left main trunk disease (n=28), severe tortuous lesions, and
everely calciﬁed vessels (n=41) were also excluded due to antici-
ated difﬁculties advancing the OCT catheters. In addition, patients
ith vessels greater than 4.0mm in diameter on angiography
n=34) were excluded, because these vessels might be too large
o occlude blood ﬂow. Therefore, 239 patients became candidates
f the follow-up OCT registry and were asked to undergo follow-
p OCT. Among these candidates, 192 patients agreed to undergo
CT at the follow-up angiography and were enrolled into the OCT
egistry. Furthermore, patients who did not take clopidogrel at
he time of the follow-up angiography (n=38) and patients who
id not agree to genetic analysis (n=21) were excluded from the
tudy. A total of 133patients (171DES)whounderwent an8-month
ollow-up coronary angiographywith OCT aswell as genetic analy-
iswereenrolledand theOCTﬁndingsof the lesionswere compared
etween patients with and without HD treatment. Also, to match
he potential differences in patients, lesions, and procedural char-
cteristics, 42 propensity-score-matched lesions (21 non-HD vs.
1 HD) were queried from the overall patient population and the
id-term OCT ﬁndings were compared between patients with and
ithout HD treatment.
ThePCI procedurewasperformedwith intravascular ultrasound
uidance (Boston Scientiﬁc Corp. or Volcano Corporation, Rancho
ordova, CA, USA).
All patients were taking aspirin 100mg/day. Clopidogrel
5mg/day was additionally given for at least 12 months after DES
mplantation. This study was approved by the Ethics Committee
f Kobe University and all enrolled study patients provided writ-
en informed consent. The study conformed to the tenets of the
eclaration of Helsinki.
oronary angiographic evaluation
As a qualitative angiographic evaluation, coronary calciﬁcation
as deﬁned as “readily apparent densities observed within the
rtery wall and site of lesion as an X-ray absorbingmass,” and clas-
iﬁed as none or mild (focal densities noted only at the margin of
nly one side of the arterial wall); moderate (i.e. not classiﬁed as
ild or severe); or severe (bulky or circulatory densities observed
n both sides of the arterial wall) [6].
Quantitative coronary angiographic evaluation (QCA) was per-
ormed for the target lesion before and after the PCI and at the time
f angiographic follow-up using dedicated software (QCA-CMS 5.1,
edis, Leiden, The Netherlands). In-stent restenosis was deﬁned
s a diameter of stenosis (DS) >50% within the stented segment.
n-stent late luminal losswas deﬁned as theminimal luminal diam-
ter immediately after PCI minus that at 8 months.
CT examinationOCT examinationwas performed 8months after stenting. In this
tudy, because frequency-domain OCT had not been approved for
linical use in Japan, time-domain OCT with coronary artery occlu-
ion was used as previously reported [7]. The entire length of thediology 64 (2014) 25–31
stent was imaged with an automatic pullback device moving at
1mm/s.
OCT analysis
All imageswere analyzedbyan independentobserver blinded to
the clinical presentation and lesion characteristics. Cross-sectional
OCT images were analyzed at 1-mm intervals (every 15 frames).
Neointimal thickness inside each stent strut was measured.
Stent area andmaximum andminimum stent diameter were mea-
sured manually. Struts with a measured neointimal thickness of
0m were deﬁned as uncovered struts. A maximum distance
of more than 170m for sirolimus-eluting stents (SES), more
than 164m for paclitaxel-eluting stents (PES), and 108m for
everolimus-eluting stents (EES) between the center reﬂection of
the strut and the adjacent vessel surfacewas deﬁned as incomplete
strut apposition [7].
To assess for asymmetric stent expansion, a stent eccentric-
ity index (SEI) was determined by the minimum stent diameter
divided by the maximum stent diameter in each cross section.
To assess the unevenness of neointimal thickness, a neointimal
unevenness score (NUS) was calculated for each cross-section as
maximumneointimal thickness in one cross-section divided by the
mean neointimal thickness of the cross-section. Then, the mean
SEI and NUS were calculated for each stent. Intra-stent thrombus
was deﬁned as a protruding mass beyond the stent strut into the
lumen with signiﬁcant attenuation behind the mass (Fig. 1). To
differentiate thrombi from plaque protrusion or neointimal hyper-
plasia, we excluded protruding masses without remarkable signal
attenuation and surface irregularity [8,9].
Blood sampling and genotyping methods
To assess the possible underlying mechanisms of subclinical
thrombus formation in HD patients, we obtained blood samples
from the arterial sheath at the time of follow-up angiography.Fig. 1. Intra-stent thrombus was deﬁned as a protruding mass beyond the stent
strut into the lumen with signiﬁcant attenuation behind the mass.
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enotyped using a TaqManTM DrugMetabolismGenotyping Assays
Applied Biosystems, Foster City, CA, USA)with the Applied Biosys-
ems 7500 Real-Time PCR System.
Also, we performed the VerifyNow P2Y12 test, and the Veri-
yNow Aspirin test (Accumetrics Inc.) for 15 randomly selected
atients out of a population of 42 propensity-matched patients.
hese tests were performed before and immediately after HD in
atients treated with HD (n=8) and for patients without HD (n=7)
t 09:00h and 13:00h, the times corresponding to the beginning
nd end, respectively, of HD treatment as previously described
10]. Brieﬂy, the test measures platelet-induced aggregation as an
ncrease in light transmittance and uses a proprietary algorithm
o report values in P2Y12 reaction units (PRU) and aspirin reac-
ion units (ARU). All laboratory testingwas performedbypersonnel
linded to patient information.
id-term clinical follow-up
Mid-termclinical follow-updatawere obtained fromoutpatient
ecord reviews or telephone interviews. Target vessel revascu-
arization was deﬁned as any re-intervention to treat a luminal
tenosis occurring in the same coronary vessel treated at the index
rocedure, within and beyond the target-lesion limits. All patients
ere followed up for at least 12 months after the index procedure.
tatistical analysis
Statistical analysis was conducted with a commercially avail-
ble software package (StatView ver.5.0, SAS Institute Inc., Cary,
C, USA, or PASWStatistics, version 18, SPSS, Inc., Chicago, IL, USA).
ontinuous variables are presented as mean± SD. Differences in
ontinuous parameters between the two groups were compared
y an unpaired t-test. Categorical variables were presented using
requency counts, and intergroup comparisons were analyzed by
isher’s exact test. Because every multiple stenting was performed
ith overlapping, statistical analysis was performed on a patient
lesion) basis. A multivariate logistic regression analysis was per-
ormed to determine whether HD was associated with thrombus
ormation. Lesion-related variables inserted into the model were
etermined when the p-value was less than 0.05 between patients
ith and without HD in univariate analyses. Step-wise regression
nalysis was further performed to validate the ﬁnding as a ﬁnal
odel. Tominimize differences in baseline characteristics between
he two groups and to validate the relationship between throm-
us formation and HD, patients were matched in a one-to-one
anner on the basis of a propensity score. The propensity scoreor each patient was calculated using a logistic regression model
11], which included a total of 13 variables (lesion type, bifur-
ation treatment, chronic total occlusion lesion treatment, use of
otablator, stent overlap, vessel disease,mean stent size, total stent
able 1
aseline patient characteristics before and after propensity score-matched population.
Before matching
HD Non-HD
(n=25) (n=96)
Baseline characteristics
Age (years) 69.16±6.67 69.99±9.38
Male sex, n (%) 16 (64%) 79 (82%)
Hypertension, n (%) 21 (84%) 78 (81%)
Dyslipidemia, n (%) 3 (12%) 63 (65%)
Diabetes mellitus, n (%) 16 (64%) 35 (36%)
Smoker, n (%) 3 (12%) 42 (43%)
*2 carriers, n (%) 11 (46%) 40 (41%)
*3 carriers, n (%) 6 (26%) 23 (23%)
alues are presented as mean± SD or percentages of patients. HD, hemodialysis.diology 64 (2014) 25–31 27
length, QCA parameters including lesion length, % diameter steno-
sis, reference vessel diameter, and minimum lumen diameter, use
ofpost-dilatation). According to thepropensity score, patientswere
selected using the nearest-neighbor method. Results are reported
with probability values. Outcomes including death, myocardial
infarction, acute coronary syndrome, target vessel revasculariza-
tion, and target lesion revascularizationwerecomparedby log-rank
test between patients with and without HD treatment. Results are
reported with probability value. A p-value of less than 0.05 was
considered to be statistically signiﬁcant.
Results
Overall populations
Of the 133 patients who underwent follow-up OCT, 12 were
excluded due to poor image acquisition. Therefore, the data for 121
patients (SES 98, PES 51, EES 3) were analyzed in the present study.
Compared with the HD patients, non-HD patients comprised more
men, and were more likely to have dyslipidemia, be current smok-
ers, CTO lesions, and have a longer total stent length. HD patients
were more likely to have diabetes mellitus, moderate/severe cal-
ciﬁcation, and require rotablation, and had greater follow-up %
diameter stenosis than non-HD patients (Tables 1 and 2). As for the
8-month OCT analysis of the overall population, 22,896 struts in
2858 cross-sectionswere analyzed.Meanminimum stent areawas
similar between the twogroups. Therewasno signiﬁcantdifference
inmean neointimal thickness, % uncovered struts, or %malapposed
struts between lesions of patients treated with and those with-
out HD. Lesions of HD patients, however, showed a smaller mean
SEI with an increased incidence of intra-stent thrombus than those
without HD (64% vs. 33%, p=0.007; Table 3). After adjustment for
demographic and angiographic differences, lesions of HD patients
had a 6-fold higher risk of in-stent thrombus formation compared
to lesions of those without HD (Table 4). With regard to major
adverse cardiac events, HD patients had more incidences of acute
coronary syndromeduring the follow-upperiod than thosewithout
HD (median: 426 days; Table 5).
Propensity-matched population
To match the baseline differences in patients, we compared
the OCT ﬁndings between lesions with and without HD among
42 propensity-score-matched lesions (21 non-HD lesions vs. 21
HD lesions). Patient, lesion, or procedural characteristics did not
signiﬁcantly differ between the two groups (Tables 1 and 2). Based
on the OCT analysis, mean stent area was similar between the two
groups.Mean neointimal thickness, % neointimal area, % uncovered
struts, and % malapposed struts were not signiﬁcantly different
between lesions of patients treated with and without HD (Table 3).
After matching
p-Value HD Non-HD p-Value
(n=21) (n=21)
0.67 69.7±7.0 70.2±10.9 0.88
0.047 14 (69%) 12 (57%) 0.48
0.75 17 (80%) 17 (80%) 0.78
0.0001 8 (38%) 8 (38%) 0.15
0.01 13 (61%) 11 (52%) 0.60
0.0034 3 (15%) 6 (28%) 0.37
0.19 7 (33%) 7 (33%) 0.44
0.82 5 (25%) 8 (38%) 0.72
28 A. Konishi et al. / Journal of Cardiology 64 (2014) 25–31
Table 2
Baseline lesion and procedural characteristics before and after propensity score-matched population.
Before matching After matching
HD Non-HD p-Value HD Non-HD p-Value
(n=28) (n=124) (n=21) (n=21)
Coronary artery
Left anterior descending, n (%) 11 (44%) 47 (48%) 0.65 10 (47%) 11 (52%) 0.75
Left circumﬂex artery, n (%) 7 (28%) 14 (14%) 0.11 7 (33%) 3 (14%) 0.14
Right coronary artery, n (%) 7 (28%) 35 (36%) 0.42 4 (19%) 7 (33%) 0.29
Type of lesion
B2/C, n (%) 13 (52%) 51 (53%) 0.92 9 (42%) 10 (47%) 0.75
Moderate/severe calciﬁcation 12 (48%) 18 (18%) 0.0026 9 (42%) 7 (33%) 0.40
Chronic total occlusion, n (%) 2 (8%) 24 (25%) 0.06 2 (9%) 4 (19%) 0.37
Bifurcation lesion, n (%) 9 (36%) 32 (33%) 0.80 8 (38%) 6 (28%) 0.51
Procedural characteristics
Total number of stents, n 28 145 23 30
Sirolimus-eluting stent, n 17 (60%) 91 (62%) 0.21 15 (65%) 17 (56%) 0.33
Paclitaxel-eluting stent, n 9 (32%) 53 (36%) 0.64 6 (26%) 13 (43%) 0.10
Everolimus-eluting stent, n 2 (7%) 1 (0.6%) 0.12 2 (8%) 0 (0%) 0.22
Total stent length (mm) 24.52±10.76 36.58±21.39 0.0074 25.19±11.31 29.19±20.63 0.44
Stent size (mm)
2.5 8 (28%) 48 (33%) 0.32 7 (30%) 12 (40%) 0.11
2.75 1 (3%) 3 (2%) 0.82 1 (4%) 2 (6%) 0.54
3.0 13 (46%) 59 (40%) 0.46 11 (47%) 9 (30%) 0.53
3.5 6 (21%) 33 (22%) 0.90 4 (17%) 6 (20%) 0.70
Maximum inﬂation pressure (atm) 14.96±2.90 14.48±3.36 0.49 14.85±3.08 13.81±4.89 0.41
Post dilatation, n (%) 8 (32%) 48 (50%) 0.10 7 (33%) 7 (33%) 0.99
Overlap stent, n (%) 7 (28%) 30 (31%) 0.75 6 (28%) 3 (14%) 0.25
Rotablation, n (%) 8 (32%) 4 (4%) 0.0001 6 (28%) 2 (9%) 0.11
Quantitative coronary angiography
Lesion length (mm) 9.93±5.15 10.98±6.13 0.43 10.05±5.31 9.02±4.69 0.50
Reference diameter (mm) 2.44±1.24 2.31±1.18 0.64 2.45±1.34 2.70±2.21 0.65
Minimum lumen diameter
Before PCI (mm) 0.61±0.37 0.53±0.38 0.38 0.58±0.37 0.71±0.37 0.37
After PCI (mm) 2.25±0.37 2.32±0.41 0.44 2.21±0.31 2.23±0.37 0.80
Follow-up (mm) 1.77±0.58 1.87±0.59 0.44 1.68±0.56 1.50±0.74 0.36
% diameter stenosis
Before PCI (%) 71.81±15.20 75.57±16.99 0.31 72.48±16.39 67.85±15.23 0.34
After PCI (%) 13.06±7.58 12.61±7.24 0.78 13.59±7.10 12.79±6.44 0.70
Follow-up (%) 35.32±22.81 25.03±19.61 0.02 36.96±23.67 36.54±29.97 0.95
Acute gain (mm) 1.63±0.37 1.78±0.49 0.05 1.62±0.37 1.57±0.47 0.66
Late loss (mm) 0.48±0.61 0.45±0.53 0.77 0.52±0.65 0.66±0.63 0.49
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Values are presented as mean± SD or percentages of patients.
D, hemodialysis; PCI, percutaneous coronary intervention.
espite the lack of a signiﬁcant difference in local OCT ﬁndings,
ntra-stent thrombus was more frequently observed in lesions of
atients with HD than in those without HD (61% vs. 19%, p=0.004)
ith a tendency toward a greater NUS in lesions of patients with
han those without HD (Table 3). Mid-term clinical follow-up data
median: 421days) were also obtained for the propensity-matched
able 3
ight-month follow-up optical coherence tomography data before and after propensity s
Before matching
HD Non-HD
(n=28) (n=124)
Mean total no of struts (n) 179.37±88.82 204.97±105.15
Minimum stent area (mm2) 5.28±1.70 5.31±1.81
Minimum lumen area (mm2) 3.65±1.44 3.83±1.76
Mean stent eccentricity index 0.87±0.03 0.89±0.03
Mean neointimal unevenness score 1.86±0.21 2.04±0.51
% of neointimal area (%) 16.97±8.21 15.49±13.64
Mean neointimal thickness (m) 152±6.6 153±12.3
Frequency of uncovered struts (%) 3.21±3.95 6.78±13.36
Frequency of malapposed struts (%) 0.99±2.03 1.43±2.73
Thrombus (%) 64 33
alues are presented as mean± SD or percentages of patients. HD, hemodialysis.population. Two deaths and ﬁve acute coronary syndrome events
were observed in the HD patients and one myocardial infarction
occurred among the non-HD patients. Eight patients in the HD
group and four patients in the non-HD group required target vessel
revascularization (Table 5). All target vessel revascularization
events were related to in-stent or edge restenosis of DES.
core-matched population.
After matching
p-Value HD Non-HD p-Value
(n=21) (n=21)
0.27 170.42±64.01 157.94±79.05 0.58
0.94 4.87±1.40 5.12±1.85 0.63
0.63 3.38±1.21 3.42±1.56 0.93
0.02 0.88±0.03 0.89±0.04 0.12
0.29 1.96±0.40 1.79±0.19 0.09
0.61 15.96±8.46 21.58±14.74 0.14
0.95 141±6.4 191±13.9 0.14
0.51 3.88±8.99 1.46±2.81 0.26
0.69 0.32±1.13 0.42±1.46 0.81
0.007 61 19 0.004
A. Konishi et al. / Journal of Cardiology 64 (2014) 25–31 29
Table 4
Multivariate logistic regression analyses to identify factors associated with thrombus formation in overall population. Model 1 includes vessel-related variables with p value
less than 0.05 between patients with and without HD in univariate analyses. Model 2 shows results by step-wise regression analysis.
Model 1 Model 2
Odds ratio 95% CI p-Value Odds ratio 95% CI p-Value
Haemodialysis 7.157 (2.102–24.369) 0.002 5.991 (1.972–18.199) 0.002
Moderate/severe calciﬁcation 0.162 (0.042–0.618) 0.008 0.230 (0.075–0.704) 0.010
Multiple stenting 0.915 (0.226–3.705) 0.900 – – –
Total stent length 1.021 (0.985–1.057) 0.253 – – –
Rotablation 1.271 (0.22–7.352) 0.789 – – –
Mean stent eccentricity index 0.001 (0–363.192) 0.301 – – –
Table 5
Eight-month clinical outcomes before and after propensity score-matching.
Before matching After matching
HD Non-HD All p-Value HD Non-HD All p-Value
N=25 N=96 N=121 (Log-rank) N=21 N=21 N=42 (Log-rank)
Death, n (%) 2 (8) 0 (0) 2 (1.7) 0.053 2 (9.5) 0 (0) 2 (4.8) 0.157
Myocardial infarction, n (%) 0 (0) 1 (1) 1 (0.8) 0.615 0 (0) 1 (4.8) 1 (2.4) 0.329
Acute coronary syndrome, n (%) 5 (20) 5 (5.2) 10 (8.3) 0.030 5 (23.8) 2 (9.5) 7 (16.7) 0.230
Target vessel revascularization, n (%) 9 (36) 13 (13.5) 22 (18.2) 0.127 8 (38.1) 4 (19) 12 (28.6) 0.331
8.2)
H
B
p
m
o
m
e
F
(
i
a
1
dTarget lesion revascularization, n (%) 9 (36) 13 (13.5) 22 (1
D, hemodialysis.
lood sampling and genotyping results in propensity-matched
opulation
The percentage of patients with CYP2C19 loss of function poly-
orphisms was comparable between the two groups. The efﬁcacy
f clopidogrel signiﬁcantly decreased immediately after HD treat-
ent in patients with HD (p=0.01; Fig. 2a), while no decrease in
fﬁcacywas observed in patientswithout HD during the same time
ig. 2. Time course of P2Y12-reaction units (PRU) before and after hemodialysis
HD) (a) Comparison of PRU between Pre HD (9 o’clock) and Post HD (13 o’clock)
n patients with HD. The efﬁcacy of clopidogrel was signiﬁcantly decreased before
nd after HD treatment in patients with HD. (b) Comparison of PRU between 9 and
3 o’clock in patients without HD treatment. The efﬁcacy of clopidogrel was not
eteriorated in patients without HD treatment. Values are presented as mean± SD.0.127 8 (38.1) 4 (19) 12 (28.6) 0.331
period (p=0.19; Fig. 2b). The efﬁcacy of aspirin did not change in
patients treated with HD (p=0.82; Fig. 3a) or in those without HD
(p=0.66) during the 4-h interval examined (Fig. 3b).
DiscussionThe ﬁndings of the present study indicated the following.
(1) In the overall population, patients with HD showed greater
Fig. 3. Time course of aspirin-reaction unit (ARU) before and after hemodialysis
(HD). (a) Comparison of ARU between Pre HD (9 o’clock) and Post HD (13 o’clock) in
patientswithHDtreatment. Theefﬁcacyof aspirinwasnot signiﬁcantlydeteriorated
before or after HD treatment in patients with HD treatment. (b) Comparison of ARU
between 9 and 13 o’clock in patients without HD treatment. The efﬁcacy of aspirin
was not deteriorated in patients without HD. Values are presented as mean± SD.
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symmetric stent expansion with an increased incidence of intra-
tent thrombus than in patients without HD. Multivariate logistic
egression analyses revealed that the risk of thrombus formation
as approximately 6-fold higher in patients with HD than in those
ithout HD. (2) Incidence of acute coronary syndrome during
ollow-up period was higher in HD patients than non-HD patients.
3) In the propensity-matched population, despite comparable
aseline characteristics, intra-stent thrombus remained signiﬁ-
antly higher in lesions with HD than in those without HD, with
tendency toward a greater NUS than non-HD patients. (4) The
fﬁcacy of clopidogrel measured by VerifyNow was signiﬁcantly
ecreased after HD treatment in patients with HD, while no alter-
tionwas observed in patients without HD during the same period.
Renal dysfunction is an important risk factor for the increased
ncidence of death and cardiovascular events [12,13]. AlthoughDES
ubstantially reduces the incidenceof in-stent restenosis compared
ith bare metal stents, HD remains a risk factor for an increased
ncidence of restenosis and major adverse clinical events after
ES implantation [14–17]. A recent Japanese nationwide registry
The Registry of Stent Thrombosis for Review and Reevaluation
RESTART)] revealed that HD is independently associated with an
ncreased incidence of late stent thrombosis [18]. Nevertheless, the
etailed mechanisms of such relation between HD therapy and
ncreased adverse events are poorly understood.
In this study, DES implanted in HD patients had a signiﬁcantly
igher incidence of subclinical thrombus than those in non-HD
atients. In general, patients with HD therapy were more likely
o have multiple coronary risk factors and prone to advanced
therosclerosis with diffuse severe calciﬁcation than non-HD
atients. Previous investigators speculated that such patient back-
round and progressed lesion characteristics might blunt the
fﬁcacy of DES rather than HD therapy itself. Indeed, in the over-
ll population of the present study, lesions in patients undergoing
D were more severely calciﬁed than lesions of patients with-
ut HD. Also, greater asymmetric stent expansion, probably due
o advanced atherosclerosis, was observed in HD lesions on follow-
p OCT images, despite greater use of rotablation performed for
D lesions than non-HD lesions. We previously reported that the
ncidence of thrombus attachment is associated with total stent
ength and mean SEI in a recent clinical OCT study based on 55
atients treated with SES [8]. Therefore, we speculate that these
atients’ background and lesion characteristics with asymmet-
ic stent expansion in HD patients might explain the somewhat
ncreased incidence of thrombus attachment in the overall popu-
ation treated with HD.
Various factorspotentially contribute to the formationof throm-
us within DES-treated lesions such as stent length, the frequency
f uncovered struts, stent eccentricity, and uneven neointimal
overage [8] and the presence of CYP2C19 loss-of-function poly-
orphisms. In the present study, it is noteworthy that the higher
ncidence of thrombus attachment remained signiﬁcant after
atching to reduce bias and confounding factors related to mul-
iple differences. Therefore, we speculated that, aside from such
atient and lesion characteristics, HD therapy itself also has a
otential impact on thrombus formation after DES implantation.
everal previous studies reported the possibility that HD activates
latelet function by increasing shear stress through theHDdialyzer
r repetitive heparin use [19]. Therefore, in this study we per-
ormed VerifyNow P2Y12 and aspirin tests to assess the efﬁcacy of
ual antiplatelet therapy for randomly selected patients from each
roup.We found that the efﬁcacy of clopidogrel deteriorated signif-
cantly immediatelyafterHDtreatment inpatients treatedwithHD,
hile no alterationwas observed in patientswithoutHDduring the
ame period. There are several possible explanations for this obser-
ation. First, platelet cells might be activated when blood passes
hrough a dialyzer. Second, sudden hypovolemic changes induceddiology 64 (2014) 25–31
byHDmight activate platelet cell function through activation of the
sympathetic nervous system [19–22]. Finally, in addition toplatelet
cell activation by HD, consumption of platelet cells by enhanced
platelet aggregation and subsequent reactive platelet cell produc-
tionmight explain the somewhat decreased efﬁcacy of clopidogrel.
Ingeneral,HDtreatment can reduce thenumberofplatelet cellsdue
to enhanced platelet aggregation induced by increased shear stress
through the HD dialyzer or heparin use. As a result, patients that
undergo HD might have greater number of platelet cells left unaf-
fected by clopidogrel, leading to deterioration of the clopidogrel
efﬁcacy in those patients.
Considering the management against the deterioration of
anti-platelet therapy, taking clopidogrel and aspirin immediately
after HD procedure or using more potent, rapid, and consistent
antiplatelet drugs could be potential therapeutic options. Admin-
istration of prasugrel or ticagrelor immediately after HD treatment
may be effective for inhibiting the aggregation function of newly
recruited platelet cells that are unexposed to antiplatelet therapy.
Limitations
The present study has several limitations. First, this was a
non-randomized, retrospective observational study based on a rel-
atively limited sample size. Although we used propensity scoring
andmatching toadjust formultiplebaselinedifferences, propensity
methods can only account for the measured variables. Therefore,
it is possible that patients with HD therapy had inherently more
diseased vessels in ways that we could not measure. Also, as with
any observational study, we cannot prove cause-and-effect rela-
tions. Therefore, it remains unclear whether HD treatment further
increases the incidenceof thrombus formation inpatients receiving
DES. Second, this study only examined SES, PES, and EES without
any comparison with bare-metal stents or other DES. Finally, the
clinical relevance of our ﬁndings remains unclear, warranting a
study involving a larger populationwith a longer follow-up period.
Conclusion
HD is a potential risk factor for subclinical thrombus attachment
afterDES therapydue to local vessel features inHDpatients. Consid-
ering the comparable results from the quantitative OCT evaluation
of the propensity-matched patients, systemic problems, such as
alteration of platelet function through HD might contribute to the
increased incidence of thrombus attachment after DES implanta-
tion. A large-scale study with longer-term follow-up is warranted
to further validate our ﬁndings.
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